Hold. BCRX's 63/100 Growth Compounder Score reflects solid biotech fundamentals, but a maxed-out Vulnerability Index (100/100)—driven by thin financial buffers and binary clinical trial risk—offset upside. Leadership Alignment at 52/100 suggests moderate founder commitment. Biotech investors need both growth *and* runway; BCRX has the former but limited margin for error.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for BioCryst Pharmaceuticals, Inc.:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 62/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates BioCryst Pharmaceuticals, Inc. (BCRX) at 62/100 — a Hold — quality is solid but valuation or risk factors cap upside. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Hold. BCRX's 63/100 Growth Compounder Score reflects solid biotech fundamentals, but a maxed-out Vulnerability Index (100/100)—driven by thin financial buffers and binary clinical trial risk—offset upside. Leadership Alignment at 52/100
BCRX's current Stocky Verdict is 62/100, placing it in the "Hold" band. This composite combines a 63/100 Compounder score, 52/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for BioCryst Pharmaceuticals, Inc. yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
BioCryst Pharmaceuticals, Inc. scores 52/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
BioCryst Pharmaceuticals, Inc.'s Vulnerability Profile scores 100/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to BioCryst Pharmaceuticals, Inc..
Sign up free and unlock the full analysis on BCRX — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
Or jump straight to the interactive dashboard for BCRX in the app.
